Doptelet® (avatrombopag) – New indication
June 27, 2019 - Dova Pharmaceuticals announced the FDA approval of Doptelet (avatrombopag), for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Download PDF
